ASND
HealthcareAscendis Pharma A/S · Biotechnology · $14B
ASND — Key Takeaways
✅ Strengths
⚠️ Areas of Concern
ASND — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Apr 8, 2026 | 56.9 | 34.1 | 46.0 | 100.0 | 63.9 | 48.5 | 0.0 |
| Apr 7, 2026 | 56.9 | 34.1 | 46.0 | 100.0 | 63.9 | 48.6 | 0.0 |
| Apr 6, 2026 | 56.9 | 34.1 | 46.0 | 100.0 | 63.9 | 48.6 | 0.0 |
| Apr 5, 2026 | 56.9 | 34.1 | 46.0 | 100.0 | 63.9 | 48.6 | 0.0 |
| Apr 4, 2026 | 56.9 | 34.1 | 46.0 | 100.0 | 63.9 | 48.7 | 0.0 |
| Apr 3, 2026 | 56.9 | 34.1 | 46.0 | 100.0 | 63.9 | 48.5 | 0.0 |
| Apr 2, 2026 | 56.9 | 34.1 | 46.0 | 100.0 | 63.9 | 48.5 | — |
ASND — Pillar Breakdown
Quality
— 34.1/100 (25%)Ascendis Pharma A/S currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 100.0/100 (20%)Ascendis Pharma A/S is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 63.9/100 (15%)Ascendis Pharma A/S maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 48.5/100 (15%)Ascendis Pharma A/S has a mixed valuation — some metrics suggest fair value while others appear stretched.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Moat
— 46/100 (30%)Ascendis Pharma A/S possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ASND.
Score Composition
More Stock Analysis
How is the ASND UQS Score Calculated?
The UQS (Unified Quality Score) for Ascendis Pharma A/S is calculated using a proprietary 5-pillar framework with 25 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Ascendis Pharma A/S's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Ascendis Pharma A/S is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.